|
?:abstract
|
-
In December 2019, a novel coronavirus known as SARS-CoV-2, emerged in Wuhan, China, causing the respiratory illness COVID-19 The WHO declared COVID-19 as Pandemic on March 12th, 2020 Therefore, the global public health authorities, research and medical communities have relied on quarantine, isolation, instauring adequate diagnosis and on supportive care for those who become ill, in order to decrease the severity of COVID-19 Regardless of these infection-control measures, to prevent the spread of the disease, the transmission of this virus is exponentially growing, hence, we require a specific antiviral agent Until April 7, 2020, according to the WHO, there are globally more than 1,300,000 confirmed cases of COVID-19 and nearly 72,000 deaths In Mexico, we are facing 2439 cases and 125 deaths and rising Therefore, it is urgent to treat the infected and optimally decrease viral shedding and subsequent transmission of SARS-CoV-2 Scientists around the world are endeavoring to find specific antivirals for the virus Several drugs such as Chloroquine, Hidroxicloroquine, Azithromycin, Interferon a, Ribavirin, Remdesivir, Favipiravir, Teicoplanin, Melatonin and Imitinab are currently undergoing clinical studies to test their efficacy and safety in the treatment of COVID-2019
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}